UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 908

Sortiert nach

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Journal of clinical oncology, 2017-04, Vol.35 (12), p.1288-1296

2017

Volltextzugriff (PDF)

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer

Cancer discovery, 2022-01, Vol.12 (1), p.74-89

2022

Volltextzugriff (PDF)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Nature communications, 2016-02, Vol.7 (1), p.10501-10501, Article 10501

2016

Volltextzugriff (PDF)

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies

Science (American Association for the Advancement of Science), 2019-08, Vol.365 (6453), p.599-604

2019

Volltextzugriff (PDF)

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C

Cell chemical biology, 2017-08, Vol.24 (8), p.1005-1016.e3

2017

Volltextzugriff (PDF)

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

Clinical cancer research, 2009-08, Vol.15 (16), p.5216-5223

2009

Volltextzugriff (PDF)

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

Cancer discovery, 2013-12, Vol.3 (12), p.1355-1363

2013

Volltextzugriff (PDF)

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

JAMA oncology, 2022-08, Vol.8 (8), p.1160

2022

Volltextzugriff (PDF)

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd

Cancer research (Chicago, Ill.), 2022-01, Vol.82 (1), p.130-141

2022

Volltextzugriff (PDF)

Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations

Journal of thoracic oncology, 2015-06, Vol.10 (6), p.951-959

2015

Volltextzugriff (PDF)

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer

Clinical cancer research, 2018-12, Vol.24 (23), p.5963-5976

2018

Volltextzugriff (PDF)

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

The Journal of clinical investigation, 2006-10, Vol.116 (10), p.2695-2706

2006

Volltextzugriff (PDF)

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer

Cancer research (Chicago, Ill.), 2022-11, Vol.82 (21), p.4079-4092

2022

Volltextzugriff (PDF)

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Cancer immunology research, 2019-09, Vol.7 (9), p.1457-1471

2019

Volltextzugriff (PDF)

Kinase drug discovery 20 years after imatinib: progress and future directions

Nature reviews. Drug discovery, 2021-07, Vol.20 (7), p.551-569

2021

Volltextzugriff (PDF)

Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8), p.2574-2586

2013

Volltextzugriff (PDF)

ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1

Molecular cell, 2022-07, Vol.82 (13), p.2443-2457.e7

2022

Volltextzugriff (PDF)

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

Nature cancer, 2022-04, Vol.3 (4), p.402

2022

Volltextzugriff (PDF)

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors

Nature communications, 2022-09, Vol.13 (1), p.5614-5614, Article 5614

2022

Volltextzugriff (PDF)

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

Cancer cell, 2006-06, Vol.9 (6), p.485-495

2006

Volltextzugriff (PDF)

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma

Cancer discovery, 2021-10, Vol.11 (10), p.2488-2505

2021

Volltextzugriff (PDF)

Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non-Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

Clinical cancer research, 2014-03, Vol.20 (5), p.1204-1211

2014

Volltextzugriff (PDF)

The quest to overcome resistance to EGFR-targeted therapies in cancer

Nature medicine, 2013-11, Vol.19 (11), p.1389-1400

2013

Volltextzugriff (PDF)

1 – 25 von 908

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(839)
Mit Volltextzugriff
(836)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(895)
Japanisch
(165)
Finnisch
(3)
Deutsch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(534)
Life Sciences & Biomedicine
(486)
Humans
(415)
Oncology
(312)
Lung Neoplasms - Drug Therapy
(198)
Female
(191)
Male
(187)
Lung Neoplasms - Genetics
(185)
Mutation
(183)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(169)
Carcinoma, Non-Small-Cell Lung - Genetics
(149)
Middle Aged
(148)
Biological And Medical Sciences
(146)
Aged
(140)
Medical Sciences
(135)
Adult
(115)
Lung Neoplasms - Pathology
(115)
Lung Cancer
(99)
Tumors
(94)
Animals
(90)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(142)
Cancer Research
(103)
Clinical Cancer Research
(76)
Journal Of Thoracic Oncology
(68)
Cancer Discovery
(26)
The New England Journal Of Medicine
(22)
Lung Cancer
(18)
Cancer
(16)
Nature
(13)
Molecular Cancer Therapeutics
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd

Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Kinase drug discovery 20 years after imatinib: progress and future directions

Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR

ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma

Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non-Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

The quest to overcome resistance to EGFR-targeted therapies in cancer

Suchergebnisse filtern